Clinical Trial
Study Details
Study Overview
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
Contacts and Locations
City of Hope
Duarte, California 91010
United States
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California 92618
United States
University of California San Francisco
San Francisco, California 94143
United States
Colorado Blood Cancer Institute
Denver, Colorado 80218
United States
Icahn School of Medicine at Mt. Sinai
New York, New York 10029
United States
Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Levine Cancer Institute
Charlotte, North Carolina 28001
United States
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania 19104
United States
MD Anderson Cancer Center
Houston, Texas 77030
United States
UZ Antwerpen
2650 Edegem
Belgium
UZ Gent
9000 Ghent
Belgium
CHU de Liege
4000 Liège
Belgium
CHU Nantes
44093 Nantes
France
CHU Lyon Sud
69495 Pierre-Bénite
France
Chu Rennes Hopital Pontchaillou
35000 Rennes
France
Institut Claudius Regaud
31100 Toulouse
France
Japanese Red Cross Medical Center
Shibuya City
150-8935
Japan
Osaka University Hospital
Suita-shi
565-0871
Japan
The Cancer Institute Hospital of JFCR
Tokyo
135-8550
Japan
VUMC Amsterdam
1081 HV Amsterdam
Netherlands
Universitair Medisch Centrum Groningen
9713 GZ Groningen
Netherlands
UMC Utrecht
3584 CX Utrecht
Netherlands
Hosp. Univ. Germans Trias I Pujol
08916 Badalona
Spain
Hosp Clinic de Barcelona
08036 Barcelona
Spain
Hosp Univ Fund Jimenez Diaz
28040 Madrid
Spain
Clinica Univ. de Navarra
31008 Pamplona
Spain
Hosp Clinico Univ de Salamanca
37007 Salamanca
Spain
University College Hospital
London
W1T 7HA
United Kingdom
Royal Marsden Hospital
Sutton
SM2 5PT
United Kingdom